Business briefs: Celgene

Share this article:

Celgene's Pomalyst (pomalidomide), an oral treatment for relapsed and refractory multiple myeloma, was approved by the FDA this week. It is the second such treatment approved for the blood cancer in the past seven months with Onyx's Kyprolis (carfilzomib) approved last July. Approval was based on response rate while clinical benefit (i.e. survival, symptoms) has not been verified by regulators. The treatment will only be available to patients through a restricted distribution program, Pomalyst REMS. Analysts forecast Pomalyst sales to reach $1.1 billion in 2017.

Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.